NanoAthero
"Smart" biodegradable nanoparticles for site-specific treatment of atherosclerosis
Η εργασία υλοποιήθηκε στο πλαίσιο της Δράσης ΕΡΕΥΝΩ - ΔΗΜΙΟΥΡΓΩ - ΚΑΙΝΟΤΟΜΩ, συγχρηματοδοτήθηκε από το Ευρωπαϊκό Ταμείο Περιφερειακής Ανάπτυξης (ΕΤΠΑ) της Ευρωπαϊκής Ένωσης και εθνικούς πόρους μέσω του Ε.Π. Ανταγωνιστικότητα, Επιχειρηματικότητα & Καινοτομία (ΕΠΑνΕΚ) (κωδικός έργου: Τ2ΕΔΚ-00563)
Acknowledgment: This research has been co‐financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE (project code: Τ2ΕΔΚ-00563)
NANOATHERO project, characterized by an interdisciplinarity, aims to the exploitation of Nanotechnology tools in order to overcome the limitation of existing cardiovascular approaches.
The main idea of "NanoAthero" is to use an Interdisciplinary methodology based on its applications Nanotechnology with Nanoparticles (NS) as transport vehicles drugs for targeted treatment of atherosclerotic plaques reducing the number of heart attacks; So, innovative approaches will be introduced to the fight against atherosclerosis, such as:
- Nanomedicine for the treatment of vulnerable plaques from smart biodegradable NS that penetrate the endothelium, reach the molecular targets within the plate and release drugs in a controlled manner.
- Innovative technologies for nano-plastic development transport of anti-inflammatory or antioxidant drugs for clinical applications .
Acronym: NanoAthero | Code: Τ2ΕΔΚ-00563
Project Full Title
Development and Preclinical Validation of biofunctionalized Nanoparticles for targeted delivery of anti-oxidant factors to treat Atherosclerosis
Partners
The Consortium is comprised of 3 partners (1 Academic & 2 SMEs)
Duration
2020 - 2022
Coordinator
Nanotechnology Lab LTFN - Aristotle University of Thessaloniki, Greece
Consortium
Nanotechnology Lab LTFN - Aristotle University of Thessaloniki (AUTH)
BL Nanobiomed P.C.
KSA SUPERALLOYS ENG
